Abbreviations Flashcards
GRP
Good Regulatory Practice
GMP
Good Manufacturing Practice
GLP
Good Laboratory Practice
GCP
Good Clinical Practice
GDP
Good Distribution Practice
GEP
Good Engineering Practice
GAMP
Good Automated Manufacturing Practice
cGMP
Current GMP
aGMP
Appropriate GMP
EIPG
European Industrial Pharmacists Group
RA
Regulatory Affairs
QP
Qualified Person
QA
Quality Assurance
R&D
Research and Development
SmPC
Summary of Product Characteristics
MAH
Marketing Authorization Holder
MA
Marketing Authorization
CMC
Chemistry, Manufacturing, and Controls
PV
Pharmacovigilance
RWE
Real-World Evidence
PMA
Progressive Marketing Authorization
ICH
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
VICH
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products
IP
Intellectual Property
HTA
Health Technology Assessment
EMA
European Medicines Agency
e-CTD
electronic Common Technical Document
CESP
Common European Submission Platform
HMA
Heads of Medicines Agencies.
SME
Small and Medium-sized Enterprise
IRP
International Reference Pricing
CA
Competent Authorities
TEU
Treaty on European Union
EU
European Union
CJEU
Court of Justice of the European Union
ECB
European Central Bank
ECA
European Court of Auditors
EDQM
European Directorate for the Quality of Medicines and HealthCare
EFTA
European Free Trade Association
EEA
European Economic Area
MP
Medicinal Product
CP
Change Proposal
EPAR
European Public Assessment Report
CHMP
Committee for Medicinal Products for Human Use
PRAC
Pharmacovigilance Risk Assessment Committee
CVMP
Committee for Medicinal Products for Veterinary Use
COMP
Committee for Orphan Medicinal Products
HMPC
Committee on Herbal Medicinal Products
PDCO
Pediatric Committee
CAT
Committee for Advanced Therapies
SAG
Scientific Advisory Groups
WP
Working Parties
SAWP
Scientific Advice Working Party
BMWP
Biosimilar Medicinal Products Working Party
ECJ
European Court of Justice
ATMP
Advanced Therapy Medicinal Products
MAA
Marketing Authorization Application
CTA
Clinical Trial Agreement
ATIMPs
Advanced Therapy Investigational Medicinal Products
PIP
Pediatric Investigation Plan
CTR
Clinical Trials Regulation
CTIS
Clinical Trials Information System
CT
Clinical Trials
MSC
Member States Concerned
MD
Medical Device
UDI
Unique Device Identifiers
CE
Conformité Européene
SUE
Serious Undesirable Effects
CPNP
Cosmetic Products Notification Portal
NHC
Nutrition and Health Claims
EFSA
European Food Safety Authority
ECHA
European Chemicals Agency
PPP
Plant Protection Products
BP
Biocidal Products
REACH
Registration, Evaluation, Authorization, and Restriction of Chemicals
NOAELS
No-Observed-Adverse-Effect-Levels
MoS
Margin of Safety
TCM
Traditional Chinese Medicine
CAM
Complementary and Alternative Medicines
MRP
Mutual Recognition Procedure
DCP
Decentralised Procedure
CMS
Concerned Member State
RMS
Reference Member State
RUP
Repeat Use Procedure
AR
Annual Report/Assessment Report
BOS
Break Out Session
CMDh
Co-ordination Group for Mutual Recognition and Decentralised Procedures
DAR
Draft Assessment Report
LOI
List of Outstanding Issues
LoQ
List of Questions
RtQ
Respons to questions
NRG
Name Review Group
IND
Investigational New Drug
FDA
U.S. Food and Drug Administration
NDA
New Drug Applicant
ANDA
Abbreviated New Drug Application
PIP
Pediatric Investigation Plan
PDCO
EMA Paediatric Committee
SPC
Supplementary Protection Certificate
Specific Product Characteristics
PUMA
Paediatric-use Marketing Authorisations
PA
Patent Application
EUnetHTA
European Network for Health Technology Assessment
API
Active Pharmaceutical Ingredient
ToC
Table of Contents
CTD
Common Technical Document
LCM
Life Cycle Management
PIL
Patient Information Leaflet
GMO
Genetically Modified Organism
QRD
Quality Review of Documents
AL
Adaptive Licensing
CMA
Conditional Marketing Authorization
RQ
Risk Quotient
PEC
Predicted Environmental Concentration
PNEC
Predicted No-Effect Concentration
RMA
Risk Minimisation Activities
RMP
Risk Management Plan
S.S.
Safety Specification
RMA
Risk Management Association
CEP
Certificate of Suitability to the European Pharmacopoeia
TSE
Trading Standards Enforcement
QOS
Quality overall Summary
MFG
Manufacturing
FPP
Finished Pharmaceutical Produc
EDMF
European Drug Master File
SM
Starting materials
DS
Drug Substance
DP
Drug Product
EoSL
End of Shelf life
(a)QbD
(analytical) Quality by Design
CQA
Critical Quality Atributes
DOEs
Design of Experiments
NOR
Normal Operating Region
MOR
Maximal Operating Region
PAR
Proven Acceptable Range
MODR
Method Operable Design Region
PAT
Process Analytical Technology
GxP
Good Experimental Practice
QTPP
Quality Target Product Profile
CQA
Critical Quality Attribute
CPP
Critical Process Parameter
RTR
Real-Time Reporting
PQS
Pharmaceutical Quality System
ECs
Established Conditions
PACMP
Post-approval Change Management Protocol
QSAR
Quantitative Structure-Activity Relationship
CAESAR
Computer- Assisted Evaluation of Industrial Chemical Substances According to Regulation
DEREK
Deductive Estimate of Risk from Existing Knowledge
PGI
Potentially Genotoxic Impurities
ADI
Acceptable Daily Intake
LOEL
Lowest Observed Effect Level
PD
Pharmacodynamics
ADME
Absorption, Distribution, Metabolism, and Excretion
GCCP
Good Cell Culture Practice
WHO
World Health Organisation
DART
Development And Reproductive Toxicity
MRSD
Maximum Recommended Starting Dose
FIH
First In Human
NCE
New Chemical Entity
HED
Human Equivalent Dose
PAD
Pharmacologically Active Dose
HEPAD
Human Equivalent Pharmacologically Active Dose
MABEL
Minimum Anticipated Biological Effect Level
CAP
Corrective Action Plan
RIP
Responsible for Information and Publicity
OTC
Over The Counter
FAGG
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten
SKP
Samenvatting van de Kenmerken van het Product
ADR
Adverse Drug reaction
NCAs
National Competent Authorities
ISO
International Organization for Standardization
RMS
Referential Management Service
SPOR portal
Substance, Product, Organisation and Referential master data
GVP
Good Pharmacovigilance Practices
PSUR
Periodic Safety Update Report
PASS
Post-Authorization Safety Study
PSMF
Pharmacovigilance System Master File
NIHDI
National Institute for Health and Disability Insurance
HCP
Healthcare Provider
CRM
Committee of Reimbursement of Medical Products
VAT
Value Added Tax
ICER
Institute for Clinical and Economic Review
Incremental cost-effectivness ratio
MOA
Mode of Action
ATC code
Anatomical Therapeutic Chemical code
HEOR
Health Economics and Outcomes Research
CEA
Cost-effectiveness Acceptability curve
BI
Budget Impact
ASMF
Active substance master file procedure
ATP
Analytical target profile
HCB
Health Care Budget
MEA
managed entry agreement
CEA
Cost-effectiveness Acceptability curve
TTC
Threshold of Toxicological Concern
ePI
electronic Product Information
PGx
Pharmacogenomics
SA
Scientific Advice/ Safety Assessment
MDR
Medical Device Regulation
MedDRA
Medical Dictionary for Regulatory Activities
SMQ
Standardised MedDRA Queries
SOC
System Organ Class
HLGT
High Level Group Term
HLT
High Level Term
PTR
Preferred Term
LLT
Lowest Level Term
DSUR
Development Safety Update Report
RO
Receptor Occupancy
QPPV
Qualified Person responsible for Pharmacovigilance
PAES
Post-Authorisation Efficacy Study
DHT
Digital Health Technologies
LBP
Live Biotherpeutic Products
IMP
Investigational Medicinal Product
EC
Ethical Committees
IVDR
In-Vitro Diagnostic Medical Devices Regulation
EUTCD
European Union Tissue and Cell Directive
BTC
Blood, Tissue and Cells
FAVV
Federaal Agentschap voor de Veiligheid van de Voedselketen
PARNUTS
Feed for Particular Nutritional Uses
FMT
Faecal Microbiota Transplants
NP
National Procedure
RIZIV
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering
INAMI
Institut national d’assurance maladie-invalidité
HTAB
Health Technology Assessment Bodies
EU-M4All
EU-Medicines for all (Article 58)
PRIME
Priority Medicines
ASMF
Active Substance Master File
ATP
Analytical Target profile
EoF
Edge of failure
IPEC
International Pharmaceutical Excipient Council
PLCM
Product Life Cycle Management
LTL
Less-than-lifetime
LoD
Limit of Detection
LoQ
Limit of Quantification
SST
System Suitabilaty Test
ALARA
As Low As Reasonable Achievable
ICSR
Individual Case Safety Report
BSA
Body Surface Area
Article 8(3) of Directive 2001/83/EC
Full Applications
Article 10 of Directive 2001/83/EC
10.1 Generic
10.3 Hybrids
10.4 Similar biological
Article 10a of Directive 2001/83/EC
Well established medicinal use (min 10 years) supported by bibliographic literature
Article 10b of Directive 2001/83/EC
New fixed combination
Article 10c of Directive 2001/83/EC
Informed consent from MAA
Article 16a of Directive 2001/83/EC
Traditional Herbals
CTD Module 1
General information
CTD Module 2
Developmental summaries
CTD Module 3
Quality
CTD Module 4
Preclinical
CTD Module 5
Clinical